Organon (OGN) Long-Term Deferred Tax (2020 - 2026)
Organon (OGN) posted quarterly Long-Term Deferred Tax of $1.5 billion for Q1 2026, up 2.82% year-over-year from $1.5 billion in Q1 2025, and little changed on a QoQ basis from $1.5 billion in Q4 2025.
Organon (OGN) Long-Term Deferred Tax (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Long-Term Deferred Tax for 7 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Deferred Tax rose 2.82% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 2.82% YoY), while the FY2025 annual figure was $1.5 billion, up 3.22% from the prior year.
- Long-Term Deferred Tax came in at $1.5 billion for Q1 2026 at Organon, roughly flat from $1.5 billion in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $1.6 billion in Q2 2025, with the low at $640.0 million in Q1 2022.
- Average Long-Term Deferred Tax over 5 years is $1.1 billion, with a median of $1.2 billion recorded in 2024.
- Across the five-year window, Long-Term Deferred Tax slipped 11.55% in 2022 and jumped 103.13% in 2024, its largest moves.
- Year by year, Long-Term Deferred Tax stood at $754.0 million in 2022, then jumped by 63.26% to $1.2 billion in 2023, then increased by 21.12% to $1.5 billion in 2024, then advanced by 3.22% to $1.5 billion in 2025, then retreated by 0.39% to $1.5 billion in 2026.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $1.5 billion, $1.5 billion, and $1.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.53 Bn |
| Dec 31, 2025 | 1.54 Bn |
| Sep 30, 2025 | 1.54 Bn |
| Jun 30, 2025 | 1.57 Bn |
| Mar 31, 2025 | 1.49 Bn |
| Dec 31, 2024 | 1.49 Bn |
| Sep 30, 2024 | 1.43 Bn |
| Jun 30, 2024 | 1.20 Bn |
| Mar 31, 2024 | 1.19 Bn |
| Dec 31, 2023 | 1.23 Bn |
| Sep 30, 2023 | 702.00 Mn |
| Jun 30, 2023 | 716.00 Mn |
| Mar 31, 2023 | 704.00 Mn |
| Dec 31, 2022 | 754.00 Mn |
| Sep 30, 2022 | 666.00 Mn |
| Jun 30, 2022 | 647.00 Mn |
| Mar 31, 2022 | 640.00 Mn |
| Dec 31, 2021 | 694.00 Mn |
| Sep 30, 2021 | 753.00 Mn |
| Jun 30, 2021 | 707.00 Mn |